CALGARY, Alberta, Sept. 03, 2024 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has recommended Shareholders vote “FOR” all the proposed resolutions at the upcoming Annual and Special Meeting of Shareholders (the “Meeting”) to be held on September 12, 2024.
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Latest posts by GlobeNewswire (see all)
- The opinion of the Supervisory Board of Enefit Green AS on the voluntary takeover bid made by Eesti Energia AS on 8 April 2025. - April 21, 2025
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zynex, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZYXI - April 20, 2025
- Writer/painter-turned cultural heritage preserver behind Spring Festival’s UNESCO heritage status success - April 20, 2025
